CMV infection in organ transplant recipients in Argentina
Part of Infections clinical trials.
This study looks at adult organ transplant recipients in Argentina who had a resistant or hard-to-treat CMV infection (a common virus that can cause problems after transplant). By reviewing their medical records, doctors hope to understand how often this happens and how it is treated to improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You had a kidney, liver, heart, lung, pancreas, or combined organ transplant.
- Your transplant was done at a participating hospital in Argentina between 2017 and 2024.
- You had a cytomegalovirus (CMV) infection within 18 months after your transplant.
- You have been followed for at least 18 months since your transplant and at least 12 months since your CMV infection started.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This study looks at how to prevent and monitor a virus called CMV after a lung transplant. It is for adults who are not carrying CMV themselves, but who receive lungs from donors who are CMV-positive, and it may help tailor safer follow-up care after transplant.
This study tracks how well ganciclovir (an antiviral medicine) works in transplant recipients who develop a resistant CMV infection. Researchers will review medical records to understand treatment success and patient outcomes.
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
This study looks at how CMV (a common virus) affects the immune system in kidney transplant patients. It may help doctors better manage CMV after transplant and improve transplant outcomes.
This trial tests whether using a blood test that measures your immune system's ability to fight CMV (a common virus) can guide when to stop anti-CMV drugs after a lung transplant, aiming to prevent the virus from causing disease.
Hear when a new Cytomegalovirus Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.